The global single cell multiomics market, valued at USD 3.2 billion in 2024, is projected to surge to USD 22.4 billion by 2034, registering a CAGR of 21.5% from 2025 to 2034. This fast-paced growth is driven by rising interest in personalized medicine, increasing chronic disease prevalence, and major investments in omics technologies.
Single-cell multiomics is revolutionizing biological research by enabling simultaneous analysis of genomics, transcriptomics, proteomics, epigenomics, and metabolomics at the single-cell level. This comprehensive view is essential to decode cellular heterogeneity and guide treatment strategies in diseases such as cancer, diabetes, and neurological disorders.
Download Full PDF Sample Copy of Market Report @ https://www.zionmarketresearch.com/buynow/su/single-cell-multiomics-market
Market Size (2024): USD 3.2 Billion
Forecast (2034): USD 22.4 Billion
CAGR (2025–2034): 21.5%
Leading Segment: Single cell genomics by product, oncology by application
Dominant Region: North America
The increasing popularity of precision medicine in developed and emerging economies is a key growth factor. As genetic screening becomes more common, single-cell analysis tools are being deployed to better understand complex diseases. This results in improved patient stratification, early diagnosis, and optimized treatments.
Advances in microfluidics, high-throughput sequencing, and data analytics (including AI and ML) are accelerating adoption. Platforms like Illumina's sequencing suite and CRISPR-based Perturb-seq are expanding research capabilities and enhancing data accuracy.
High equipment costs (e.g., Chromium from 10x Genomics, BD Rhapsody) and maintenance contracts make adoption challenging, especially for smaller research institutions. Closed-system designs requiring proprietary reagents also increase the total cost of ownership.
Companies like Illumina, Bio-Rad, and Mission Bio are investing in single-cell technologies. In February 2025, Illumina announced new omics applications leveraging their advanced sequencers, expanding single-cell readouts for CRISPR and spatial analysis.
There’s a major gap in standardized protocols across platforms and labs. Inconsistent cell preparation, nucleic acid extraction, and data reporting make it hard to compare or replicate results, which limits clinical translation and regulatory acceptance.
For More Information or Query, Visit @ https://www.zionmarketresearch.com/report/single-cell-multiomics-market
Single Cell Genomics (largest share)
Single Cell Proteomics
Single Cell Metabolomics
Single Cell Transcriptomics
Oncology (leading)
Immunology
Cell Biology
Neurology
Academic and Research Organizations (leading)
Pharmaceutical & Biotechnology Companies
Hospitals and Diagnostic Laboratories
Others
North America (dominant due to funding and infrastructure)
Europe
Asia Pacific
Latin America
Middle East & Africa
North America leads the market, with strong support from government and private sectors. For instance, in May 2025, Pluto Bio raised $3.6 million to improve AI-based multi-omics tools for drug development in the U.S. and Europe.
Key players driving market innovation include:
10x Genomics
CELLENION
PerkinElmer Inc.
Illumina Inc.
Bio-Rad Laboratories Inc.
Mission Bio
AstraZeneca
Singleron Biotechnologies
CYTENA GmbH
BD
These firms are enhancing scalability, precision, and integration of multiomic platforms.
1. What is single-cell multiomics? It refers to the integrated analysis of multiple types of omics data (like genomics, transcriptomics, proteomics) from the same individual cell.
2. Why is the market growing so rapidly? Growing chronic disease prevalence, rising demand for precision medicine, and technological innovations are key drivers.
3. Which region leads the market? North America, due to its strong research infrastructure and presence of leading market players.
4. What are the main applications? Oncology is the largest application area, followed by immunology and neurology.
5. What challenges does the industry face? High operational costs and lack of standardization in protocols are the biggest hurdles.